Levetiracetam |
![]() Last updated: 10/09/2025 |
![]() |
(Not known by any other names) |
|
![]() |
|
A veterinary anticonvulsant drug used in animals and humans | |
---|---|---|
|
Use to help prevent epilepsy and seizures | |
|
Dogs; Cats |
Approval status |
|
Not approved | |
---|---|---|
|
Not approved |
Chemical structure |
|
Levetiracetam exhibits optical isomerism, specifically chirality, due to the presence of a single chiral centre in its pyrrolidone ring structure. This gives rise to two enantiomers: S-levetiracetam and R-levetiracetam. The clinically used form is S-levetiracetam, which has been shown to possess superior anticonvulsant activity compared to its R-enantiomer. | |
---|---|---|
|
C₈H₁₄N₂O₂ | |
|
CCC(C(=O)N)N1CCCC1=O | |
|
CC[C@@H](C(=O)N)N1CCCC1=O | |
|
HPHUVLMMVZITSG-LURJTMIESA-N | |
|
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1 | |
|
Yes |
|
![]() |
Common Name | Relationship | Link |
---|---|---|
levetiracetam | - | ![]() |
General status |
|
Medicinal drug: anti-epileptic | |
---|---|---|
|
Fatty amide | |
|
- | |
|
R-levetiracetam is considered an impurity - pharmacopoeial standards requiring its content to be typically less than 0.8% | |
|
Synthetic | |
|
Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. | |
|
[Synaptic vesicle glycoprotein 2A, Agonist], [Voltage-dependent N-type calcium channel subunit alpha-1B, Inhibitor] | |
|
102767-28-2 | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Antiepileptics | |
|
QN03AX14 | |
|
No | |
|
- | |
|
170.21 | |
|
(2R)-2-(2-oxopyrrolidin-1-yl)butanamide | |
|
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Crystalline solid |
Commercial |
|
|
|||
---|---|---|---|---|
|
Current | |||
|
1999, first approval for human use USA; Early 2000, off-label use for animals | |||
|
|
|||
|
|
|||
|
Usually formulated in various tablet forms including those for immediate-release, and extended-release tablets as well as liquid solutions for oral administration | |||
|
Levetiracetam is produced through a multi-step chemical synthesis beginning with (S)-2-aminobutyric acid, which serves as the chiral starting material. This compound undergoes acylation with ethyl chloroacetate, forming an intermediate that is then subjected to cyclisation to create the pyrrolidone ring structure central to levetiracetam’s activity. Following this, a hydrolysis step removes the ester group, yielding the active pharmaceutical ingredient in its desired enantiomeric form. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
298000 | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) 3 = Unverified data of known source |
High | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
2.29 X 10-01 | Calculated | - | |||||||
|
-0.64 | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) 3 = Unverified data of known source |
Low | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
Intravenous LD₅₀ = 1038 mg kg⁻¹ | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) Rat3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
66% of the dose is renally excreted unchanged. | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Possible liver toxicant CNS toxicant - may cause somnolence, decreased energy, headache, dizziness, and coordination difficulties |
Handling issues |
|
|
|||
---|---|---|---|---|
|
Will emit toxic fumes when heated to decomposition | |||
|
Health: H302, H319 | |||
|
Not listed (Not listed) | |||
|
Not regulated | |||
|
- | |||
|
- |
|
![]() |
|
|
||
---|---|---|---|
|
levetiracetam | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 10/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |